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A B S T R A C T
Human bocavirus (HBoV) is a parvovirus whose association with respiratory disease is currently 
under investigation. 
Objective: To determine HBoV prevalence in children with lower acute respiratory infection.
Methods: We investigated HBoV in 433 nasopharyngeal aspirates collected in 2007-2009 from 
children 0 to 5 years old hospitalized with bronchiolitis or pneumonia in Córdoba, Argentina.
Results: The general prevalence of HBoV was 21.5% and the positive cases (HBoV+) were more 
frequent during winter and spring. The mean age of HBoV+ patients was 6.9 months, with 87.1% 
of the detections corresponding to infants less than 1 year old (among which the prevalence of 
HBoV was 26.3% in patients < 3 months of age, 22.1% in 3 to 6 months, 25.3% in 6 to 9 months, 
and 18.8% in 9 to 12 months). The sequence analysis of the NP1 coding region of 15 isolates 
showed that all isolates from Cordoba were HBoV1 which exhibited a homology of nearly 100% 
both among themselves and with the originally discovered virus from 2005. 
Conclusion: Overall, our results indicate that HBoV is a significant pathogen that contributes to 
acute respiratory infection both on its own and during coinfection with other viruses. 
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Introduction 
Human bocavirus (HBoV) is a parvovirus first identified in 
2005 in nasopharyngeal aspirates (NPA) of children with 
lower respiratory tract infection.1 Since then, it has been 
associated with acute infection of the upper and lower 
respiratory tract (ARI), which is a major cause of doctor’s 
office visits and hospitalization and has a high impact on 
morbidity and mortality, particularly among children in 
developing countries.2,3 With a ubiquitous distribution,4 the 
presence of HBoV DNA in patients with ARI has been reported 
mainly in children ranging from ~ 5 to 19%,5-13 although a 
higher prevalence (106 of 318 cases of illness, i.e. 33%) has been 
described recently.14 Even though the virus is often associated 
with upper and lower ARI, the high rates of coinfection with 
other respiratory viruses with well established pathogenic 
potential6,9,10,12,15-18 and the possibility of a persistent 
infection14,19,20 make it difficult to evaluate the etiological role 
of HBoV in respiratory disease. 
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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As the other members in the genus Bocavirus, the HBoV 
genome is organized in three open reading frames, which 
encode the non-structural proteins NP1 (genus-specific) 
and NS1 and the structural proteins VP1/VP2.1 Currently 4 
different species of human bocavirus have been proposed and 
the name HBoV1 has now been suggested for the originally 
discovered virus.21
The aim of this study was to determine the circulation of HBoV 
in Córdoba, Argentina, and to identify the epidemiological pattern 
of the infection in preschool-age children with lower ARI.
Materials and methods
Patients and clinical samples 
The procedures of this study were evaluated and approved 
by the Ethics Committee of the Hospital Nacional de Clínicas, 
Universidad Nacional de Córdoba. Four hundred and thirty-three 
clinical specimens, consisting of NPA, from 433 patients aged 
0 to 5 years old, hospitalized with a diagnosis of bronchiolitis 
or pneumonia of suspected viral etiology, were collected under 
a surveillance program of pneumonia in Córdoba (patients 
with immunosuppression, active pulmonary TBS or positive 
baciloscopy, cystic fibrosis and nosocomial pneumonia were 
not included). The study involved the detection of HBoV in NPA 
collected in 2007, 2008 and 2009. Samples from 2007 (n = 100), 
2008 (n = 33), and 2009 (n = 300) were stored at -20ºC.
Nucleic acid extraction from clinical specimens
Nucleic acids were extracted from NPA using the method of 
guanidine buffer and silica by Boom et al.,22 with modifications 
as described below. A 50-µL NPA aliquot was added to the 
preassembled reaction buffer, containing 10 µL silica and 
100 µL lysis buffer (0.1 M Tris pH 6.4, 37 mM EDTA pH 8.0, 
0.22 g/mL Triton X-100, 1.2 g/mL guanidine isothiocyanate), and 
then vortexed for 10 sec. After incubation for 10 min at room 
temperature, the mixture was vortexed again (5 sec) and briefly 
centrifuged for 5 sec to spin down (0 to 3,700 rpm) in a Labnet 
(Woodbridge, NJ, USA) microcentrifuge. The supernatant 
was discarded and next the silica-nucleic acid pellet was 
subsequently washed twice with ethanol 70% (v/v), and once 
with acetone. After disposal of the acetone, the pellets were 
dried at 56ºC with open lids in a Labnet (Woodbridge, NJ, 
USA) heat block for 10 min. Elution buffer (25 µl TE buffer, 
pH 8.0, without RNase inhibitor) was added, and the vessel was 
closed, vortexed briefly, and incubated for 15 min at 56ºC. The 
vessel was briefly vortexed again and centrifuged for 2.5 min at 
16,000 x g, and the supernatant containing DNA and RNA was 
stored at -20ºC for later use in the PCR reactions.
Detection of human bocavirus genome by PCR 
A region of HBoV DNA comprising nucleotides 2354 to 2684 
was amplified with previously published primers,1 resulting 
in a fragment of 354 bp. Each PCR reaction consisted of 0.2 mM 
dNTPs, 0.4 µM forward and reverse primers mix, 2.5 mM MgCl2, 
0.02 U/µL Platinum Taq DNA polymerase (Invitrogen), and 
2 µL of nucleic acid extract. The cycling conditions included 35 
rounds of the sequence 94ºC, 30 sec; 48ºC, 30 sec; 72ºC, 1 min; 
with a previous cycle at 94ºC for 2 min and a final extension 
at 72ºC for 10 min. Appropriate negative and positive controls 
were included (the positive controls were kindly provided by 
Cristina Videla and Guadalupe Carballal, CEMIC, Buenos Aires). 
The PCR products were visualized on 8.5% polyacrylamide gels 
stained with silver solution (0.11 M AgNO3).
DNA sequencing of human bocavirus NP1 region
Fifteen isolates from 2007 and 2009 were used for sequence 
analysis from which a region corresponding to the NP1 
protein of HBoV was amplified by nested PCR. Each PCR 
reaction was performed with 0.25 mM dNTP mix and 
5 U/µL EX Taq Hot Start Version DNA polymerase (TaKaRa), in 
the buffer provided by the manufacturer, for a total volume of 
50 µL. For the first round 5 µL template and 0.20 µM of each 
primer HBoV_2204F (5’GAG ACA TCG CAA GTG GAC TAT3’) 
and HBoV_3101R (5’TTG AGC AGC GCG ATC AGC GTT A3’) 
were used. For the nested reaction 5 µL template of the first 
round was used and 40 µM of each of the primers HBoV_2321F 
(5’GCA CAG CCA CGT GAC GAA GAT GA3’) and HBoV_3056R 
(5’GGA TTA AAT GGC CCA AGA TA3’). The final product 
had an expected size of 736 nt. Amplified fragments were 
purified following agarose-gel electrophoresis by using a 
QIAquick gel extraction kit (Qiagen). Sequencing reactions 
were performed bidirectionally by using appropriate primers 
and cycle-sequencing kits (ABI PRISM BigDye Terminator v. 3.1; 
PE Applied Biosystems) and resolved by using a 3100 Genetic 
Analyzer (Applied Biosystems).
Sequence analysis
Phylogenetic analysis included our 15 isolates (3 from 2007 
and 12 from 2009) and representative previous isolations 
available at GenBank (HBoV1 EF203921; HBoV1 DQ340570; 
HBoV1 DQ000495; HBoV1 DQ000496; HBoV2 GU048663; HBoV2 
GU048662; HBoV2 GU048664; HBoV2 FJ170279; HBoV2 FJ170280; 
HBoV2 GQ200737; HBoV2 EU082214; HBoV2 FJ948860; HBoV3 
HM132056; HBoV3 GU048665; HBoV3 FJ948861; HBoV3 EU918736; 
HBoV3 CQ867666; HBoV4 FJ973561; CnMV AB158475; CnMV 
AF495467; and BPV DQ335247). For cataloguing and storage, 
sequences were input into free online sequence-alignment 
software (ALIGN Query, GENESTREAM SEARCH network server 
IGH, Montpellier, France; http://xylian.igh.cnrs.fr/bin/align-
guess.cgi). Phylogenetic analysis was conducted with MEGA 
version 5.03 software (available at http://www.megasoftware.
net) using the neighbour-joining method.
Analysis of epidemiological and clinical features associated 
with HBoV infection
We analyzed clinical and epidemiological aspects associated 
with samples positive for HBoV (HBoV+), based on the 
information recorded in the official form of the network 
monitoring pneumonia. An approximation of the rate of 
coinfection with other respiratory viruses was obtained 
from diagnostic assays for respiratory syncytial virus (RSV), 
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parainfluenza 1/2/3 (PIV), influenza A and B (Flu) and adenovirus 
(AV) in the patients who were HBoV+. These assays (RSV, PIV, 
Flu and AV) were performed by direct immunofluorescence 
assay in the hospital facilities as part of the diagnostic testing 
required for the patients in the network reporting survey. 
We also analyzed epidemiological and clinical data of HBoV+ 
patients who at the same time were negative for RSV, PIV, Flu, 
AV, and blood culture. Quantitative and qualitative variables 
were compared using Student’s t test or Chi square test, 
respectively, with a level of significance of 0.05.
Results
Characteristics of the study population
The average age of all patients included in the study was 8.84 
months [standard deviation (SD): 11.1 months], with 345/433 
(79.7%) of the samples from children ≤ 12 months. Out of 
433 samples, 337 (77.8%) were collected during the fall and 
winter, while 245/433 (56.6%) were male patients. 
Prevalence of HBoV
The general prevalence of HBoV was 93/433 (21.5%), with 
16/100 (16%) positive samples (HBoV+) in 2007, 9/33 (27.3%) 
in 2008, and 68/300 (22.6%) in 2009 (Table 1). In an attempt 
to estimate the rate of coinfection among our HBoV+ 
specimens, we used the diagnostic test results available for 
RSV, PIV, Flu, and AV. Forty nine out of 93 HBoV+ samples 
(52.7%) were coinfected with at least one of the above 
viral agents (Table 1). The majority of the coinfections, 
47/49 (95.9%) were single coinfections and 40/49 (81.6%) 
were HBoV-RSV coinfections. Two cases with multiple 
coinfecting viruses were detected (one NPA from 2007 and 
the other from 2009) and in both cases HBoV was detected 
in conjunction with RSV and PIV.
Other epidemiological features associated with HBoV infection
The mean age of the 93 HBoV+ patients was 6.9 months 
(SD: 8.9 months; median: 5 months). HBoV was detected in 
the entire age range included in the study (10 days to 60 
months), but 81/93 (87.1%) were under 12 months (Fig. 1). 
The prevalence of HBoV per age group in children 0-1 year 
old was as follows: 30/114 (26.3%) in the 0 to 3 months group; 
21/95 (22.1%) in the 3 to 6 months group, 17/67 (25.4%) in the 
6 to 9 months group, and 13/69 (18.8%) in the 9 to 12 months 
group. HBoV infections were detected throughout the year 
except in the summer (a season during which only 11 
NPA were collected in 2007 and none in the other years 
included in the study). However, HBoV+ cases were 
concentrated in the winter season (Fig. 2). The distribution 
of HBoV+ cases plotted together with RSV, PIV and Flu by 
Fig. 1 - Distribution of HBoV+ cases by age groups, 2007-2009. 
Year HBoV+ Patients with HBoV                          Coinfections
  
in coinfection
RSV PIV Flu A AV
2007 16/100
(16%)
5/16
(31.3%)
2/5
(40%)
3/5
(60%)
- -
2008 9/33
(27.3%)
4/9
(44.4%)
4/4
(100%)
- - -
2009 68/300
(22.7%)
40/68
(58.8%)
34/40 
(85%)
2/40
(5%)
4/40 
(10%)
-
Total
 
93/433
(21.5%)
49/93
(52.7%)
40/49
(81.6%)
5/49
(10.2%)
4/49
(8.2%)
0
Table 1 - Percentage of HBoV+ clinical specimens and co-detection with other respiratory viruses (VRS, PIV, Flu A 
and/or AV)
n   120
100
80
60
40
20
0
NPA tested
Age (months)
HBoV
0-
3
3-
6
6-
9
9-
12
12
-1
5
15
-1
8
18
-2
1
21
-2
4
24
-2
7
27
-3
0
30
-3
3
33
-3
6
36
-3
9
39
-4
2
42
-4
5
48
-5
1
51
-6
0
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epidemiological week shows the overlapping circulation 
of these respiratory viruses mainly during the winter 
months (Fig. 2, epidemiological weeks 21 through 40), 
with a difference in the peaks of maximum frequency 
of detection between RSV (weeks 25-28) and HBoV 
(weeks 33-36).
Signs and symptoms associated with HBoV infection
We analyzed laboratory data and clinical manifestations of 
17 patients whose NPA were HBoV+ but negative for all other 
diagnostic assays performed (RSV, PIV, Flu, AV, and blood 
culture, Table 2). Most patients had fever of 39ºC or higher 
Fig. 2 - Distribution of HBoV+ cases and co-circulation with other respiratory viruses by range of 
epidemiological week and season, 2007-2009.
Nº Year EW Sex Age (mo) T W C RD F ≥ 39ºC R D Ts-cs (d) L
1 2009 28 F 7 + - - + + - - 2 17200
2 2009 30 F 10 + - + + + - + 23 14500
3 2009 30 M 7 - - + + + - - 1 3100
4 2009 31 F 10 - - - - + - - 4 21500
5 2009 33 M 9 + - + - + - - 3 22200
6 2009 33 F 8 - - + + + - - 2 10300
7 2009 33 M 9 - - - - + + - 2 23300
8 2009 34 F 9 - - + + - + - 3 10800
9 2009 36 M 12 + - - + + - - 2 23100
10 2009 43 M 6 - - + + + - - 4 9300
11 2008 35 M 3 + - + - + - - 8 14100
12 2008 32 F 14 - - + - + - - NA NA
13 2007 28 M 3 + + - - + + - 8 22200
14 2007 28 M 12 + + + + + - + 1 19300
15 2007 28 M 3 - - - - - - - NA NA
16 2007 28 M 48 + - + + + - - 5 9200
17 2007 41 M 36 + - - + - - - 4 18000
EW, epidemiological week; T, tachypnea; W, wheezing; C, cough; RD, respiratory distress; R, rhinorrhoea; D, desnutrition; Ts-cs, time between 
onset of symptoms and clinical sample (NPA, at the moment of hospitalization) in days; L, leukocyte count; +, yes; -, no; NA, data not available.
Table 2 - Clinical and epidemiological data of 17 HBoV+ patients -negative for RSV, PIV, Flu, AV, and blood culture
n   120
100
80
60
40
20
0
RSV PI FLU HBoV NPA tested
1-4 5-8 9-12 13-16 17-20 21-24 25-28 29-32 33-36 37-40 41-44 45-48 48-52
 Summer Autumn Winter Spring
 Epidemiological week and season
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and white blood cell count higher than the normal range 
(> 10.8 x 103/mm3). HBoV detection was also associated with 
respiratory distress (59% of cases), cough (59%) and tachypnea 
(53%). Wheezing and rhinorrhea were observed in some cases. 
Three of the 4 cases with a more conspicuous illness had high 
fever, respiratory distress, cough and tachypnea (2 of these 
were associated with malnutrition). The average number of 
days between the onset of symptoms and hospitalization (at 
which time the respiratory sample for diagnosis was taken) was 
4.8 days. In addition, these cases occurred in epidemiological 
weeks 28 through 43 (winter – spring) and the average age 
of the patients was 12.1 months [not significantly different 
from the average age in all HBoV+ cases (p = 0.051)].
To further assess the clinical picture associated with HBoV 
infection, the features of this group of 17 HBoV+ patients were 
compared to the features of 17 patients with a positive detection 
for RSV only (Table 3). The RSV+ group consisted of patients 
whose NPA had a positive detection for RSV and were negative 
for all other assays performed, taken randomly among the 
RSV+ clinical specimens in this study. Significant differences 
were found in the comparisons “range of epidemiological 
weeks” of occurrence of cases (as evidenced in Fig. 2) and 
“average number of days between onset of symptoms 
and hospitalization”. Also, patients with RSV were more likely 
to present tachypnea and cough, whereas patients with HBoV 
were more likely to have high fever and leukocytosis (Table 3). 
Sequence analyses
Fifteen HBoV isolates were sequenced to perform phylogenetic 
analysis and the genomic region analyzed consisted of 
the complete NP1 coding region between nucleotides 2321 
and 3056 of the HBoV genome. All 15 isolates grouped with 
HBoV1 (Fig. 3). Only 3 isolates exhibited any degree of genetic 
diversity, namely a substitution at nt 2733 which changed a 
T to a C (genetic distance: 0.001), revealing an extremely high 
similarity among the isolates and also in comparison with the 
original HBoV1 sequence.
Fig. 3 - Neighbor-joining tree showing phylogenetic relationships among HBoV1, HBoV2, HBoV3, HBoV4, CnMV, BPV and 
15 local HBoV sequences (*) amplified after nucleic acid extraction from nasopharyngeal aspirates of pediatric patients with 
bronchiolitis or pneumonia. The phylogenetic analysis was done using the region comprising nt 2321 through 3056 (NP1) 
of the HBoV1 genome.
146 RT AR07 *
359 HP AR09 *
320 HP AR09 *
256 HP AR09 *
260 HP AR09 *
307 HP AR09 *
327 HP AR09 *
414 SF AR09 *
366 HP AR09 *
131 HP AR07 *
132 HP AR07 *
488 HP AR09 *
EF203921 HBoV1 TL07
DQ340570 HBoV1 US06
EF450738 HBoV1 KH07
326 HP AR09 *
398 HP AR09 *
462 HP AR09 *
DQ000495 HBoV1 SW05
DQ000496 HBoV1 SW05
GQ867667 HBoV3 BR04
GQ867666 HBoV3 BR03
EU918736 HBoV3 AU09
FJ948861 HBoV3 AU02
HM132056 HBoV3 CH07
GU048665 HBoV3 UK08
FJ170279 HBoV2 PK09
 Fj948860 HBoV2 AU01
  GU048664 HBoV2 UK08
 EU082214 HBoV2 AU09
 FJ170280 HBoV2 UK09
 GU048663 HBoV2 TL07
 GU0048662 HBoV2 TL07
  DQ335247 BPV US07 
AB158475 CnMV JP05 
AF495467 CnMV US03
HBoV genotype 1
HBoV genotype 3
HBoV genotype 4
HBoV genotype 2
Bovine parvovirus
Canine minute virus
0.05
FJ973561 HBoV4 NG10
    GQ200737 HBoV2 PK10
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Discussion 
In this report, we describe epidemiological and clinical features 
associated with HBoV1 infection in 0 to 5 year-old children with 
bronchiolitis or pneumonia in Córdoba, Argentina, revealing 
a high prevalence of HBoV (21.5%) in the population studied. 
The age range of HBoV+ cases extended from 10 days to 5 
years, with an average age of 6.9 months. Most HBoV+ patients 
(87.1%) were less than 1 year old (Fig. 1); likewise other authors 
found the main prevalence of HBoV in approximately the same 
range.6,11,23 Interestingly, HBoV1 prevalence was similar in 
the age ranges under 1 year (26.3% in < 3 months, 22.1% in 
3 to 6 months, 25.4% in 6 to 9 months, and 18.8% in 9 to 12 
months). Since initially HBoV had been detected in patients 
5-6 months of age and over,1,24,25 some authors proposed that 
maternal antibodies prevent neonatal infection by HBoV.10,26,27 
However, we found high and similar HBoV1 prevalence among 
1-3 months and 3-6 months infants, suggesting an incidence of 
HBoV1 infection very early in life. Remarkably, we and others 
have detected HBoV as early as few days after birth8,28 and a 
seroepidemiological study also provided evidence that HBoV 
infection is common during early infancy.29
HBoV+ cases occurred in fall through spring and peaked 
during the winter, overlapping with other respiratory viruses 
such as RSV, PIV and Flu (Fig. 2). Similar findings have been 
reported,6,12,16,18,24,30 although some studies found HBoV cases 
throughout the year with spring outbreaks.5,15,31,32 The higher 
frequency of detection in the winter months suggests a maximum 
incidence of HBoV1 infection in this season as well. However, 
most surveys on HBoV1 so far analyze samples collected for 
diagnosis of ARI, which is the reason for the predominance of 
samples collected during fall/winter, as in the present study. 
The rate of coinfection was at least 52.7%. This can be 
taken as estimation, since HBoV was detected by PCR, while 
coinfection with other respiratory viruses was determined 
based on immunofluorescence assay. Even so, noticeably over 
80% of the coinfections are HBoV1-RSV coinfections (Table 1). 
Others also recognized elevated percentages of coinfection with 
RSV among HBoV+ patients.6,11,13,16,25 If the circulation pattern 
is confirmed as it is presumed (mainly in infants less than 1 
year old and during winter) this high rate of coinfection could 
be an effect of cocirculation (Fig. 2), although an interaction 
between these viruses cannot be disregarded.
Clinical manifestations concomitant with HBoV1 detection 
included high fever (≥ 39ºC), leukocytosis, cough, and respiratory 
distress (Table 2). Also, fewer days were observed between onset 
of symptoms and hospitalization in HBoV+ cases compared 
to RSV+ cases (Table 3), which indicated a less insidious 
development of a severe form of the associated disease.
Finally, the phylogenetic analysis of 15 local isolates from 
2007 and 2009 confirmed that all of them were genotype 1 
(Fig. 3), showing an extremely high homology with the original 
sequence identified in 2005, in agreement with the low nucleotide 
substitution rate in the NP1 region of HBoV1 shown recently.21 
The primers used in the present work were designed to detect the 
four genotypes of HBoV identified to date, yet all of the isolations 
sequenced belonged to genotype 1. Thus, our results reflect the 
association of HBoV1 with acute respiratory infection.
Conclusion
This is the first report of HBoV1 in Argentina. Our results 
suggest that HBoV1 plays an important role in respiratory 
illness that causes significant disease both on its own and in 
conjunction with other coinfecting viruses. 
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Clinical / epidemiological aspects RSV HBoV p
Range of epidemiological weeks (seasons) 17-38 
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Fever > 39ºC 11/17 (64.7%) 14/17 (82.4%) < 0.001
Rhinorrhoea 2/17 (11.8%) 3/17 (17.6%) 0.068
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Table 3 - Comparison of clinical presentations and epidemiological features of 17 RSV+ patients versus 17 HBoV+ 
patients
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